In March 2023 the Company announced the successful development of a new novel platform of anti-cancer mRNA therapeutics, being the Company's fifth program and the third in its Midkine family. In June 2023 the Company successfully completedin vitrostudies for the anti-cancer mRNA therapeutic in br...
KEVIN MCNAIR Chief Financial Officer 23 April 2021 K E Y P E R FO R M A N C E I N D I C ATO R S ("KPIs") KPI Revenue Gross margin Adjusted EBITDA profit/(loss) Adjusted EBITDA margin Operating profit External net debt Order Book Cash Net Assets Average number of employees 31/...